Garmin, a US-based company better known for its GPS and fitness tracking technology, has introduced the Venu 2 Plus, its top smartwatch, with an electrocardiogram (ECG) app that has undergone clinical testing. The app, which has received US Food and Drug Administration (FDA) approval, uses already-installed sensors on the watch to record the electric signals generated by users' hearts in order to assist users in keeping a closer eye on their heart health.
Consumer wearables have been equipped with ECG capabilities for some time, but getting these tools approved can be difficult. However, Garmin's app has undergone clinical validation, adding significantly to the business' already potent platform. Eligible users can use the app right away to record ECG readings on demand while wearing their wrists. The app will show the results of the heart rhythm after thirty seconds.
The app can examine user results for potential health issues like early symptoms of atrial fibrillation (AFib). Users will receive a history of their ECG readings from the app if it is synced with Garmin Connect, which can then be shared with medical professionals.
The ECG app is currently only accessible on Venu 2 Plus and is only available to US users. Garmin has, however, stated that it intends to continue growing the launch in the future to include more products. Additionally, as the business obtains the required regulatory approval in additional regions, the app will be made available to more users.
Users must make sure their device is running the most recent Garmin Connect version in order to use the ECG app on their Venu 2 Plus. Users of the ECG app now have more control over their heart health and can easily share their findings with medical professionals, making it a useful tool for those who want to monitor their condition closely.